Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Osteosarcoma
  • Bone Sarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Melanoma
  • Non -Small Cell Lung Cancer
  • Pancreatic Cancer
  • Synovial Sarcoma
  • Refractory Sarcoma
  • Sarcoma
  • Sarcoma, Ewing
  • Solid Tumor
  • Soft Tissue Sarcoma
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced solid tumors in Phase 1 and BA30...

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced solid tumors in Phase 1 and BA3011 alone and in combination with nivolumab in Phase 2. Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct 2019) and a dose expansion phase (still enrolling). Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12 and over.

Tracking Information

NCT #
NCT03425279
Collaborators
Not Provided
Investigators
Not Provided